FDA grants orphan drug status to experimental Cushing’s therapy

FDA grants orphan drug status to experimental Cushing’s therapy

The U.S. Food and Drug Administration (FDA) has granted orphan drug designation to Lundbeck’s asedebart, a designation that may provide incentives for the development of this experimental antibody for endogenous Cushing’s syndrome. A Phase 2 trial is currently underway in people with Cushing’s disease, one form of the syndrome. “This milestone reflects the strength of […] The post FDA grants orphan drug status to experimental Cushing’s therapy a…